Month: June 2016

We’ve recently reported that an immunotoxin targeting mesothelin produced durable major

0 comments

We’ve recently reported that an immunotoxin targeting mesothelin produced durable major tumor regressions in patients with extensive treatment refractory mesothelioma. by many solid tumors it is a stylish immunotherapy target. Antibody based therapies currently Gemcitabine HCl (Gemzar) in clinical trials include an immunotoxin a chimeric monoclonal antibody and an antibody drug conjugate. In addition a ….  Read More

Signaling from the mammalian target of rapamycin (mTOR) takes on an

0 comments

Signaling from the mammalian target of rapamycin (mTOR) takes on an important part in the modulation of both innate and adaptive immune responses. also found that rapamycin significantly enhanced anti-inflammation activity of regulatory T cells (Tregs) which decreased production of pro-inflammatory cytokines and chemokines by macrophages and microglia. Depletion of Tregs partially elevated macrophage/microglia-induced neuroinflammation ….  Read More